Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come

被引：12
作者：
Hitzler, Johann [1 ,2 ]
Estey, Elihu [3 ,4 ]
机构：
[1] Hosp Sick Children, Div Hematol Oncol, Toronto, ON, Canada
[2] Hosp Sick Children, Res Inst, Dev & Stem Cell Biol, Toronto, ON, Canada
[3] Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
来源：
HAEMATOLOGICA | 2019年 / 104卷 / 01期
关键词：
ACUTE MYELOGENOUS LEUKEMIA; CD33; EXPRESSION; ADULT PATIENTS; CHEMOTHERAPY; SURVIVAL; IMPACTS;
D O I：
10.3324/haematol.2018.205948
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7 / 9
页数：3
相关论文
共 18 条
[1]   Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission [J].
Burnett, Alan K. ;
Goldstone, Anthony ;
Hills, Robert K. ;
Milligan, Donald ;
Prentice, Archie ;
Yin, John ;
Wheatley, Keith ;
Hunter, Ann ;
Russell, Nigel .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1293-1301
[2]   Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study [J].
Castaigne, Sylvie ;
Pautas, Cecile ;
Terre, Christine ;
Raffoux, Emmanuel ;
Bordessoule, Dominique ;
Bastie, Jean-Noel ;
Legrand, Ollivier ;
Thomas, Xavier ;
Turlure, Pascal ;
Reman, Oumedaly ;
de Revel, Thierry ;
Gastaud, Lauris ;
de Gunzburg, Noemie ;
Contentin, Nathalie ;
Henry, Estelle ;
Marolleau, Jean-Pierre ;
Aljijakli, Ahmad ;
Rousselot, Philippe ;
Fenaux, Pierre ;
Preudhomme, Claude ;
Chevret, Sylvie ;
Dombret, Herve .
LANCET, 2012, 379 (9825) :1508-1516
[3]   Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work [J].
deLima, M ;
Strom, SS ;
Keating, M ;
Kantarjian, H ;
Pierce, S ;
OBrien, S ;
Freireich, E ;
Estey, E .
BLOOD, 1997, 90 (12) :4719-4724
[4]   New drug approvals in acute myeloid leukemia: what's the best end point? [J].
Estey, E. ;
Othus, M. ;
Lee, S. J. ;
Appelbaum, F. R. ;
Gale, R. P. .
LEUKEMIA, 2016, 30 (03) :521-525
[5]   No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials [J].
Gale, Rosemary E. ;
Popa, Teodora ;
Wright, Melissa ;
Khan, Naeem ;
Freeman, Sylvie D. ;
Burnett, Alan K. ;
Russell, Nigel H. ;
Hills, Robert K. ;
Linch, David C. .
BLOOD, 2018, 131 (04) :468-471
[6]   Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 [J].
Gamis, Alan S. ;
Alonzo, Todd A. ;
Meshinchi, Soheil ;
Sung, Lillian ;
Gerbing, Robert B. ;
Raimondi, Susana C. ;
Hirsch, Betsy A. ;
Kahwash, Samir B. ;
Heerema-McKenney, Amy ;
Winter, Laura ;
Glick, Kathleen ;
Davies, Stella M. ;
Byron, Patti ;
Smith, Franklin O. ;
Aplenc, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3021-+
[7]   Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials [J].
Hills, Robert K. ;
Castaigne, Sylvie ;
Appelbaum, Frederick R. ;
Delaunay, Jacques ;
Petersdorf, Stephen ;
Othus, Megan ;
Estey, Elihu H. ;
Dombret, Herve ;
Chevret, Sylvie ;
Ifrah, Norbert ;
Cahn, Jean-Yves ;
Recher, Christian ;
Chilton, Lucy ;
Moorman, Anthony V. ;
Burnett, Alan K. .
LANCET ONCOLOGY, 2014, 15 (09) :986-996
[8]   Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia [J].
Kantarjian, Hagop ;
Stein, Anthony ;
Goekbuget, Nicola ;
Fielding, Adele K. ;
Schuh, Andre C. ;
Ribera, Josep-Maria ;
Wei, Andrew ;
Dombret, Herve ;
Foa, Robin ;
Bassan, Renato ;
Arslan, Onder ;
Sanz, Miguel A. ;
Bergeron, Julie ;
Demirkan, Fatih ;
Lech-Maranda, Ewa ;
Rambaldi, Alessandro ;
Thomas, Xavier ;
Horst, Heinz-August ;
Brueggemann, Monika ;
Klapper, Wolfram ;
Wood, Brent L. ;
Fleishman, Alex ;
Nagorsen, Dirk ;
Holland, Christopher ;
Zimmerman, Zachary ;
Topp, Max S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09) :836-847
[9]   Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia [J].
Khan, N. ;
Hills, R. K. ;
Virgo, P. ;
Couzens, S. ;
Clark, N. ;
Gilkes, A. ;
Richardson, P. ;
Knapper, S. ;
Grimwade, D. ;
Russell, N. H. ;
Burnett, A. K. ;
Freeman, S. D. .
LEUKEMIA, 2017, 31 (05) :1059-1068
[10]   CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531 [J].
Lamba, Jatinder K. ;
Chauhan, Lata ;
Shin, Miyoung ;
Loken, Michael R. ;
Pollard, Jessica A. ;
Wang, Yi-Cheng ;
Ries, Rhonda E. ;
Aplenc, Richard ;
Hirsch, Betsy A. ;
Raimondi, Susana C. ;
Walter, Roland B. ;
Bernstein, Irwin D. ;
Gamis, Alan S. ;
Alonzo, Todd A. ;
Meshinchi, Soheil .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2674-+
12